BSE Pharma Sector Regulatory Filings — August 14, 2026

14-08-2026

Alkem Laboratories reported consolidated revenue from operations of ₹37,401.5 million for Q1 FY27, a 10.9% YoY increase, driven by 10.3% growth in India sales and 16.0% growth in international sales. However, net profit (after non-controlling interest) declined 21.7% YoY to ₹5,200 million, impacted by higher R&D spend and exceptional items in the prior year. The company also announced the acquisition of a majority stake in Occlutech Holding AG, Switzerland, via its subsidiary Alkem Medtech Private Limited, completed on July 16, 2026.

• · The Daman (India) formulations facility received an Official Action Indicated (OAI) status in August 2026 following an April 2026 inspection.
• · The company's standalone profit from continuing operations was ₹5,699.8 million, down 8.4% YoY from ₹6,222.6 million.
• · Exceptional items in Q1 FY26 included a gain of ₹142.9 million from the sale of the Indore manufacturing facility; no exceptional items were recorded in Q1 FY27.
• · The company opted for the new tax regime (Section 115BAA) from FY27, impacting deferred tax recognition.
• · Shareholding as of June 30, 2026: Promoters 49.7%, Institutions 33.1%, Non-Institutions 17.3%.
• · Market capitalisation was ₹665,894 million as of June 30, 2026.

14-08-2026

Alkem Laboratories Limited has informed the stock exchanges that its Board of Directors approved setting up a new block within the existing manufacturing facility at Baddi, Himachal Pradesh, with an investment of up to INR 75 crores. This is a routine capacity expansion disclosure under SEBI LODR Regulations and does not include any financial performance data or period-over-period comparisons.

• · The new block will be set up within the existing manufacturing facility at Baddi, Himachal Pradesh.
• · The disclosure is made under Regulation 30 of SEBI LODR Regulations.
• · A copy of the disclosure will be available on the company's website.

14-08-2026

Alkem Laboratories reported Q1FY27 revenue of ₹37,402 Mn, up 10.9% YoY, driven by 10.3% growth in India sales and 16.0% growth in international sales. EBITDA grew 3.7% YoY to ₹7,661 Mn with a margin of 20.5%. However, net profit declined sharply by 21.7% YoY to ₹5,200 Mn, and EBITDA margin contracted from 21.9% to 20.5% YoY. The company also received an OAI (Official Action Indicated) status for its Daman facility following an April 2026 inspection.

• · The Daman formulations facility received an Official Action Indicated (OAI) status in August 2026 following an April 2026 inspection.
• · The Taloja R&D Bioequivalence Centre received no observations from its April 2026 inspection.
• · The company's domestic sales contribution to total sales decreased to 67.1% from 68.2% in Q1FY26.
• · US business sales contribution to total sales decreased to 20.0% from 21.0% in Q1FY26.
• · Non-US international sales contribution increased to 12.9% from 10.8% in Q1FY26.
• · The company outperformed IPM in seven key focused therapies: Anti-infectives (~1.1X), Gastro-intestinal (~1.2X), VMN (~1.4X), Pain (~1.8X), Anti-Diabetic (~1.4X), Respiratory (~1.6X), and Derma (~1.6X).
• · Alkem has 15+ years of unmatched leadership in the Anti-Infectives therapy.
• · The company has 20 state-of-the-art manufacturing facilities.
• · Share price as of June 30, 2026 was ₹5,570 on NSE.
• · Promoter & Promoter Group held 49.7%, Institutions 33.1%, and Non-Institutions 17.3% as of June 30, 2026.

14-08-2026

Alkem Laboratories has announced the availability of the audio recording of its Q1FY27 earnings conference call on its website. This is a routine disclosure under SEBI LODR regulations, providing investors access to the call. No financial figures or performance details are included in this filing.

• · Audio recording of Q1FY27 earnings call is available at https://www.alkemlabs.com/investors/earnings-call

14-08-2026

Ipca Laboratories Limited held its 76th Annual General Meeting on August 13, 2026, where all six resolutions were passed by the requisite majority. While resolutions such as adoption of financial statements and dividend declaration received near-unanimous support (over 99.98% in favour), the re-appointment of Mr. Prashant Godha as Executive Director saw significant dissent, with 9.74% of total votes cast against it, including 19.25% opposition from public institutional shareholders.

• · The voting period for remote e-voting was August 10-12, 2026, with the cut-off date for entitlement being August 7, 2026.
• · No shareholders attended in person or through proxy; all 57 attendees joined via video conferencing.
• · All resolutions were ordinary resolutions, and none involved promoter/promoter group interest.
• · Resolution 5 (re-appointment of Mr. Prashant Godha) saw the highest opposition: 22,441,508 votes against (9.74% of total polled), with public institutional holders casting 19.25% against.
• · Resolutions 2 (dividend) and 6 (cost auditors) passed with near 100% approval (only 166 and 259 votes against, respectively).
• · No invalid votes were recorded for any resolution.

14-08-2026

Aurobindo Pharma's wholly owned subsidiary Eugia Pharma Specialities Ltd. received a Warning Letter from the US FDA for its Unit I formulation manufacturing facility, following a prior OAI status. The company stated there is no impact on existing US supplies, and the unit contributes only ~2% to group revenue, limiting the financial materiality.

• · Unit I had previously received Official Action Indicated (OAI) status from the US FDA on May 24, 2026.
• · The Warning Letter was issued subsequent to the OAI status.
• · The company is committed to working with the US FDA to enhance compliance.